Advanced oral delivery of peptides and small molecules present complex challenges regarding solubility and permeability. Enteris BioPharma offers a proven solution with our innovative oral drug delivery technology, Peptelligence®.
Peptelligence® utilizes a unique multifaceted approach to increase the solubility and absorption of peptides. Enteris has demonstrated positive results in several clinical studies, including pivotal Phase 3 trials. As a true full-service partner of choice, Enteris BioPharma is uniquely qualified to provide integrated support from the earliest stages of research through late stage clinical trials.
ORAL DRUG DELIVERY MECHANISM
Enteris BioPharma’s clinically proven, cutting edge oral drug delivery technology, Peptelligence®, enables the oral delivery of molecules that are typically injected, including peptides and BCS Class II, III, and IV small molecules, in an enteric-coated tablet formulation.
Enteris’ formulation technology is made up of two key components, the first is a permeation enhancer, which loosens tight junctions in the intestinal enterocytes and allows paracellular transport. The permeation enhancer, a surfactant, also acts as a great solubilizing agent. The other main excipient, citric acid, also plays an active, multifunctional role in transport by acting as a calcium chelator and membrane permeation enhancer, a pH-lowering agent that increases absorptive flux, and a membrane wetting/charge dispersal agent.
Enteris has demonstrated its ability to effectively deliver a variety of molecules across multiple therapeutic indications.